Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL
Status:
Not yet recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
ENKTL is a highly aggressive NHL with a higher incidence in Asia. L-asparaginase containing
chemotherapy regimens are the standard first-line treatment with apparently toxicities. In
2020 ASH, we reported Sintilimab(anti-PD-1 antibody) plus Chidamide(an oral subtype-selective
HDACi) yielded effective antitumor activity, durable response in patients with relapsed or
refractory ENKTL(SCENT trial. Abstracts 644). We next conducted a exploratory study to
investigated the safety and efficacy of Sintilimab plus Chidamide(SC) for patients with newly
diagnosed ENKTL(SCENT-2 trial).